Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.
Fred Hutch Cancer Center established Partners in Science 2.0 @ Fred Hutch, a summer research program that trains middle school and high school teachers in Fred Hutch labs to expand hands-on learning experiences they can take back to the classroom.
FDA issued a draft guidance, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” to assist medical product sponsors in submitting diversity action plans to support certain clinical studies.
Researchers at Baylor College of Medicine and collaborating institutions have uncovered new potential therapeutic targets for cancer and new insights into existing cancer drug targets.
Researchers at MD Anderson Cancer Center have demonstrated that therapeutically restoring ‘youthful’ levels of a specific subunit of the telomerase enzyme can significantly reduce the signs and symptoms of aging in preclinical models.
The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute researchers have found a potentially effective drug-combination approach to treating certain patients with non-small cell lung cancer.
Both Tai Chi and cognitive behavioral therapy can reduce insomnia in breast cancer survivors but also may provide additional health benefits by reducing inflammation and bolstering anti-viral defenses, according to a study led by UCLA Health researchers. The work was published in Brain, Behavior, and Immunity.
Starpax Biopharma Inc. announced its Starpax Cancer Treatment Platform, an innovation using living, self-propelled, non-pathogenic bacteria that carry anticancer drugs on their surface and are sensitive to magnetic fields.
FDA approved Epkinly (epcoritamab-bysp) for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
The European Commission approved Fruzaqla (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.
